Home

uniQure N.V. - Ordinary Shares (QURE)

54.31
+1.66 (3.15%)
NASDAQ · Last Trade: Sep 27th, 11:05 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close52.65
Open51.00
Bid53.96
Ask54.06
Day's Range49.20 - 55.11
52 Week Range4.450 - 55.11
Volume11,296,863
Market Cap2.98B
PE Ratio (TTM)-13.85
EPS (TTM)-3.9
Dividend & YieldN/A (N/A)
1 Month Average Volume5,882,064

Chart

About uniQure N.V. - Ordinary Shares (QURE)

Uniqure is a biotechnology company focusing on the development of gene therapies for the treatment of genetic diseases. The company is dedicated to creating innovative and transformative therapies that target various conditions, particularly those related to genetic disorders and rare diseases. By leveraging advanced gene-editing technologies, Uniqure aims to provide long-lasting solutions that address the underlying causes of these ailments. Their pipeline includes research and development efforts centered on delivering effective treatments to improve patients' lives through the unique potential of gene therapy. Read More

News & Press Releases

Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slidebenzinga.com
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · September 27, 2025
uniQure Announces Pricing of Upsized $300 Million Public Offering
LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $300 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 947,368 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about September 29, 2025, subject to the satisfaction of customary closing conditions.
By uniQure Inc. · Via GlobeNewswire · September 25, 2025
UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Streetbenzinga.com
UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease gene therapy.
Via Benzinga · September 25, 2025
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursdaybenzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · September 25, 2025
uniQure Stock Jumps On Positive News, But Risks Remainbenzinga.com
uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in treating Huntington's disease.
Via Benzinga · September 25, 2025
Wall Street Pauses AI Frenzy as Oracle Seeks $15B in Fresh Fundingchartmill.com
After weeks of record highs fueled by AI optimism, U.S. stocks cooled for a second straight day. Oracle’s massive debt raise and divergent moves in chipmakers set the tone, while housing and lithium stole part of the spotlight.
Via Chartmill · September 25, 2025
Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Todaybenzinga.com
U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85.
Via Benzinga · September 24, 2025
UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’stocktwits.com
UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026.
Via Stocktwits · September 24, 2025
uniQure Announces $200 Million Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $200 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to a number of additional ordinary shares equal to 15% of the total number of ordinary shares (and ordinary shares underlying pre-funded warrants) sold in the public offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
By uniQure Inc. · Via GlobeNewswire · September 24, 2025
Nasdaq Down Over 100 Points; US Crude Oil Stocks Fallbenzinga.com
Via Benzinga · September 24, 2025
What's Going On With UniQure Stock Wednesday?benzinga.com
UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington's Disease.
Via Benzinga · September 24, 2025
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Todaystocktwits.com
Via Stocktwits · September 24, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · September 24, 2025
A Cure For Huntington's Disease? UniQure Launches More Than 240%.investors.com
The company's gene therapy slowed disease progression by 75% over three years.
Via Investor's Business Daily · September 24, 2025
uniQure Stock Doubles On Promising Data From Huntington's Disease Trialbenzinga.com
UniQure's AMT-130 gene therapy slowed Huntington's disease progression in a Phase 1/2 trial, supported by new $175 million financing for launch readiness.
Via Benzinga · September 24, 2025
uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trialstocktwits.com
The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale.
Via Stocktwits · September 24, 2025
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~
By uniQure Inc. · Via GlobeNewswire · September 24, 2025
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~
By uniQure Inc. · Via GlobeNewswire · September 24, 2025
uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Diseasebenzinga.com
uniQure's early AMT-191 trial data in Fabry disease showed strong enzyme activity, manageable safety, and patient independence from enzyme replacement therapy.
Via Benzinga · September 5, 2025
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~
By uniQure Inc. · Via GlobeNewswire · September 5, 2025
FDA Outlines Process To Speed Up Rare Disease Therapy Approvalsbenzinga.com
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
Via Benzinga · September 4, 2025
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Directionbenzinga.com
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
Via Benzinga · August 11, 2025
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?benzinga.com
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.
Via Benzinga · July 30, 2025
uniQure Narrows Loss in Fiscal Q2fool.com
Via The Motley Fool · July 29, 2025
uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shareschartmill.com
uniQure NV reports mixed Q2 2025 results with revenue missing estimates but EPS beating forecasts. Shares rise on regulatory progress for Huntington's gene therapy AMT-130.
Via Chartmill · July 29, 2025